These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 35750857)

  • 1. ctDNA guides omission of adjuvant chemotherapy for stage II CRC.
    Romero D
    Nat Rev Clin Oncol; 2022 Aug; 19(8):493. PubMed ID: 35750857
    [No Abstract]   [Full Text] [Related]  

  • 2. ctDNA-guided adjuvant chemotherapy for colorectal cancer-ready for prime time?
    Andersen CL; Heitzer E
    Cancer Cell; 2022 Sep; 40(9):911-913. PubMed ID: 36055230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer.
    Taniguchi H; Nakamura Y; Kotani D; Yukami H; Mishima S; Sawada K; Shirasu H; Ebi H; Yamanaka T; Aleshin A; Billings PR; Rabinowitz M; Oki E; Takemasa I; Kato T; Mori M; Yoshino T
    Cancer Sci; 2021 Jul; 112(7):2915-2920. PubMed ID: 33931919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study.
    Tie J; Wang Y; Cohen J; Li L; Hong W; Christie M; Wong HL; Kosmider S; Wong R; Thomson B; Choi J; Fox A; Field K; Burge M; Shannon J; Kotasek D; Tebbutt NC; Karapetis C; Underhill C; Haydon A; Schaeffer J; Ptak J; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    PLoS Med; 2021 May; 18(5):e1003620. PubMed ID: 33939694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tailoring adjuvant chemotherapy by circulating tumor DNA (ctDNA) in older patients with stage II-III colon cancer.
    Akagündüz B; Guven DC; Ozer M; Okten IN; Atag E; Unek İT; Tatli AM; Karaoglu A
    J Geriatr Oncol; 2023 Mar; 14(2):101367. PubMed ID: 36038467
    [No Abstract]   [Full Text] [Related]  

  • 6. Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study.
    Schraa SJ; van Rooijen KL; van der Kruijssen DEW; Rubio Alarcón C; Phallen J; Sausen M; Simmons J; Coupé VMH; van Grevenstein WMU; Elias S; Verkooijen HM; Laclé MM; Bosch LJW; van den Broek D; Meijer GA; Velculescu VE; Fijneman RJA; Vink GR; Koopman M;
    BMC Cancer; 2020 Aug; 20(1):790. PubMed ID: 32819390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survival.
    Murray DH; Symonds EL; Young GP; Byrne S; Rabbitt P; Roy A; Cornthwaite K; Karapetis CS; Pedersen SK
    J Cancer Res Clin Oncol; 2018 Sep; 144(9):1741-1750. PubMed ID: 29992492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer.
    Kotani D; Oki E; Nakamura Y; Yukami H; Mishima S; Bando H; Shirasu H; Yamazaki K; Watanabe J; Kotaka M; Hirata K; Akazawa N; Kataoka K; Sharma S; Aushev VN; Aleshin A; Misumi T; Taniguchi H; Takemasa I; Kato T; Mori M; Yoshino T
    Nat Med; 2023 Jan; 29(1):127-134. PubMed ID: 36646802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
    Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
    JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS).
    Benhaim L; Bouché O; Normand C; Didelot A; Mulot C; Le Corre D; Garrigou S; Djadi-Prat J; Wang-Renault SF; Perez-Toralla K; Pekin D; Poulet G; Landi B; Taieb J; Selvy M; Emile JF; Lecomte T; Blons H; Chatellier G; Link DR; Taly V; Laurent-Puig P
    Eur J Cancer; 2021 Dec; 159():24-33. PubMed ID: 34731746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
    Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The CIRCULATE Trial: Circulating Tumor DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation (AIO-KRK-0217).
    Folprecht G; Reinacher-Schick A; Weitz J; Lugnier C; Kraeft AL; Wisser S; Aust DE; Weiss L; von Bubnoff N; Kramer M; Thiede C; Tannapfel A
    Clin Colorectal Cancer; 2022 Jun; 21(2):170-174. PubMed ID: 34772609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcriptional signatures for coupled predictions of stage II and III colorectal cancer metastasis and fluorouracil-based adjuvant chemotherapy benefit.
    Song K; Guo Y; Wang X; Cai H; Zheng W; Li N; Song X; Ao L; Guo Z; Zhao W
    FASEB J; 2019 Jan; 33(1):151-162. PubMed ID: 29957060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Principles of oncologic drug therapy following surgery for bowel cancer].
    Ristamäki R; Ålgars A
    Duodecim; 2016; 132(12):1155-9. PubMed ID: 27483631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating Tumour DNA as a Potential Cost-Effective Biomarker to Reduce Adjuvant Chemotherapy Overtreatment in Stage II Colorectal Cancer.
    To YH; Degeling K; Kosmider S; Wong R; Lee M; Dunn C; Gard G; Jalali A; Wong V; IJzerman M; Gibbs P; Tie J
    Pharmacoeconomics; 2021 Aug; 39(8):953-964. PubMed ID: 34089503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mina53 nuclear localization is an important indicator of prognosis in patients with colorectal cancer after adjuvant chemotherapy.
    Fujino S; Kinugasa T; Sudo T; Mizobe T; Yoshida T; Yoshida N; Ohchi T; Tajiri K; Yuge K; Nagasu S; Katagiri M; Akagi Y
    Oncol Rep; 2018 Jul; 40(1):101-110. PubMed ID: 29750310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
    Stanisavljević L; Myklebust MP; Leh S; Dahl O
    Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Adjuvant therapy of colorectal cancers].
    Joensuu H; Kellokumpu I
    Duodecim; 1997; 113(8):705-13. PubMed ID: 11466869
    [No Abstract]   [Full Text] [Related]  

  • 19. Impact of Dose Reductions, Delays Between Chemotherapy Cycles, and/or Shorter Courses of Adjuvant Chemotherapy in Stage II and III Colorectal Cancer Patients: a Single-Center Retrospective Study.
    Sgouros J; Aravantinos G; Kouvatseas G; Rapti A; Stamoulis G; Bisvikis A; Res H; Samantas E
    J Gastrointest Cancer; 2015 Dec; 46(4):343-9. PubMed ID: 26143067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PLA2 (group IIA phospholipase A2) as a prognostic determinant in stage II colorectal carcinoma.
    Buhmeida A; Bendardaf R; Hilska M; Laine J; Collan Y; Laato M; Syrjänen K; Pyrhönen S
    Ann Oncol; 2009 Jul; 20(7):1230-5. PubMed ID: 19276398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.